MXCT (MXCT) revenue breakdown
By product, Product sales is the largest at 57% of fiscal 2025 revenue, growing 6% a year over 6 years.
By region, Inside the United States is the largest at 64% of fiscal 2025 revenue; Outside the United States grew fastest, 16% a year over 2 years.
Revenue by product
Fiscal years, as MXCT reports them in its 10-K filings; fiscal 2025 total $33M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Product sales | $13M | $15M | $21M | $28M | $19M | $21M | $19M | 57% |
| Licenses | — | — | — | — | — | $16M | $12M | 37% |
| Assay and other service revenue | — | — | — | — | — | — | $2M | 6% |
| Other | $339,400 | $601,300 | $784,600 | $1M | $897,000 | $1M | — | — |
Revenue by region
Fiscal years, as MXCT reports them in its 10-K filings; fiscal 2025 total $33M.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Inside the United States | $32M | $26M | $21M | 64% |
| Outside the United States | $9M | $13M | $12M | 36% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MXCT.
Open MXCT in InvestinglyQuestions
Where does MXCT make its money?
In fiscal 2025, by product: Product sales $19M, Licenses $12M, Assay and other service revenue $2M.
From MXCT's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.